Streamlining AAV And LVV Manufacturing With Integrated Platform Solutions

Cell and gene therapies are redefining the future of medicine by offering groundbreaking treatment options for diseases once deemed incurable. Central to these therapies are viral vectors—particularly Adeno-Associated Vectors (AAV) and Lentiviral Vectors (LVV)—which serve as essential tools for gene delivery. Despite their promise, these therapies face significant manufacturing challenges, including process complexity and scalability issues, as well as the urgent need for safe and efficient production methods. AGC Biologics is addressing these challenges with the development of innovative, ready-to-use manufacturing platforms such as BravoAAV and ProntoLVV, designed to streamline and accelerate viral vector production.

Designed with scalability and flexibility in mind, these platforms streamline viral vector production by integrating shared process steps, equipment, and standardized reagents. Their “plug and play” model supports rapid transition to GMP manufacturing, with timelines as short as 9–12 months from plasmid. With optimized workflows, scalable bioreactor systems, and a strong foundation in Quality by Design. Discover how these manufacturing platforms can help you scale smarter and bring your therapies to patients more efficiently.